| Code | CSB-RA006163MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Quavonlimab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, thereby dampening immune responses. This inhibitory pathway plays a pivotal role in maintaining immune homeostasis and self-tolerance, but can be exploited by tumors to evade immune surveillance. Dysregulation of CTLA4 signaling is implicated in various cancers and autoimmune disorders, making it a significant target for immunotherapeutic intervention.
Quavonlimab represents a next-generation anti-CTLA4 antibody engineered to selectively deplete CTLA4-expressing regulatory T cells while minimizing systemic immune activation, distinguishing it from earlier CTLA4-targeting agents. This biosimilar antibody serves as a valuable research tool for investigating CTLA4 biology, tumor immunology, immune checkpoint mechanisms, and the development of novel cancer immunotherapy strategies. It enables researchers to explore T-cell regulation and immune modulation in preclinical studies.
There are currently no reviews for this product.